Oliver Gruber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oliver Gruber has a total of 438 co-authors. Here are the top co-authors by number of shared publications:
- Jens Treutlein
Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University
5 shared publications Bernd Krämer
Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, University Hospital Heidelberg, Heidelberg, Germany
4 shared publications- Bernd Krämer
Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Germany
4 shared publications - Kang Sim
West Region, Institute of Mental Health, Singapore
3 shared publications Karolin E. Einenkel
Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, University Hospital Heidelberg, Heidelberg, Germany
3 shared publications- Peter Falkai
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany
3 shared publications
Latest Publications
- Open Access
Structural brain network organization and aggressive behavior in schizophrenia: a mega-analysis of 2260 patients and 3058 healthy controls from the ENIGMA-Schizophrenia Working Group
Background: Although most individuals with schizophrenia do not show aggressive behavior, rates are higher than in the general population. Identifying the neurobiological correlates of aggression may inform prevention. Methods: We included 2260 individuals with schizophrenia spectrum disorders and 3058 healthy controls (HC) from 26 sites in the ENIGMA-Schizophrenia Working Group. The former were classified as showing at least moderate aggression (SZ+A; N = 231) or not (SZ−A; N = 2029) based on symptom rating scales. Structural covariance networks were constructed from cortical and subcortical volumes. We examined global and nodal network topology, as well as density within six large-scale brain networks and between each network and the rest of the brain. Metrics were summarized as the area under the curve (AUC) across a prespecified range of densities ( K = 0.10–0.25, Δ K = 0.01). Group differences were assessed using pairwise permutation tests with Benjamini–Hochberg correction for multiple comparisons. Results: Global and nodal network topology did not differ significantly between SZ+A and HC. Network–rest density of the salience network (SN) was higher in SZ+A than in HC, although this difference did not survive multiple-comparison correction (ΔAUC = 0.018, p BH = .083). In exploratory subgroup analyses, higher SN network–rest density was observed only in SZ+A with high delusion severity (ΔAUC = 0.021, p = .007). By contrast, SZ−A demonstrated extensive alterations in global network topology compared with SZ+A and HC, alongside selective alterations in nodal topology and large-scale network density compared with HC. Results were broadly consistent across sensitivity analyses using alternative definitions of aggression and adjusting for current antipsychotic dose. Conclusions: SZ+A was characterized by fewer—not more—abnormalities in structural covariance network organization than SZ−A, which may reflect etiological heterogeneity. In SZ+A with high delusion severity, higher network–rest density of the SN may point to aberrant salience processing in aggressive behavior.
Open AccessStructural brain network organization and aggressive behavior in schizophrenia: a mega-analysis of 2260 patients and 3058 healthy controls from the ENIGMA-Schizophrenia Working Group
Background: Although most individuals with schizophrenia do not show aggressive behavior, rates are higher than in the general population. Identifying the neurobiological correlates of aggression may inform prevention. Methods: We included 2260 individuals with schizophrenia spectrum disorders and 3058 healthy controls (HC) from 26 sites in the ENIGMA-Schizophrenia Working Group. The former were classified as showing at least moderate aggression (SZ+A; N = 231) or not (SZ−A; N = 2029) based on symptom rating scales. Structural covariance networks were constructed from cortical and subcortical volumes. We examined global and nodal network topology, as well as density within six large-scale brain networks and between each network and the rest of the brain. Metrics were summarized as the area under the curve (AUC) across a prespecified range of densities ( K = 0.10–0.25, Δ K = 0.01). Group differences were assessed using pairwise permutation tests with Benjamini–Hochberg correction for multiple comparisons. Results: Global and nodal network topology did not differ significantly between SZ+A and HC. Network–rest density of the salience network (SN) was higher in SZ+A than in HC, although this difference did not survive multiple-comparison correction (ΔAUC = 0.018, p BH = .083). In exploratory subgroup analyses, higher SN network–rest density was observed only in SZ+A with high delusion severity (ΔAUC = 0.021, p = .007). By contrast, SZ−A demonstrated extensive alterations in global network topology compared with SZ+A and HC, alongside selective alterations in nodal topology and large-scale network density compared with HC. Results were broadly consistent across sensitivity analyses using alternative definitions of aggression and adjusting for current antipsychotic dose. Conclusions: SZ+A was characterized by fewer—not more—abnormalities in structural covariance network organization than SZ−A, which may reflect etiological heterogeneity. In SZ+A with high delusion severity, higher network–rest density of the SN may point to aberrant salience processing in aggressive behavior.
- 26 June 2026
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (7) , 3343-3356
Neuropathophysiological changes associated with mirtazapine treatment response in major depressive disorder: insights into bottom-up dopaminergic pathways and prefrontal control networks
Major depressive disorder (MDD) shows striking heterogeneity in both symptoms and underlying pathophysiology, and the absence of biologically grounded subtypes often results in a prolonged trial-and-error process when selecting effective treatments. This has motivated efforts to identify biomarkers that may predict individual treatment responses. Although mirtazapine is widely used and its efficacy is well established in clinical settings, neuroscientific studies on its treatment response remain limited relative to other antidepressants. To address this gap, this study examined pre-treatment pathophysiological neural features associated with subsequent response to mirtazapine. Sixty-seven individuals with MDD underwent functional magnetic resonance imaging during a conditioned reward task and then received monotherapy with mirtazapine or one of two comparator antidepressants (agomelatine or a selective serotonin reuptake inhibitor). Mirtazapine responders demonstrated increased pre-treatment activation in core components of the mesolimbic dopaminergic pathway, particularly the ventral tegmental area and ventral striatum, as well as in prefrontal and functionally connected regions implicated in reward evaluation, reward-related behavioral inhibition, and reward-based decision-making. Importantly, many of these response-related activations were specific to the mirtazapine group. These findings suggest that altered engagement of mesolimbic dopaminergic pathways and prefrontal regulatory networks during reward processing may characterize an MDD subtype responsive to mirtazapine, and that such patterns may serve as biomarkers for identifying patients likely to benefit from this treatment.
- 26 June 2026
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (7) , 3343-3356
Neuropathophysiological changes associated with mirtazapine treatment response in major depressive disorder: insights into bottom-up dopaminergic pathways and prefrontal control networks
Major depressive disorder (MDD) shows striking heterogeneity in both symptoms and underlying pathophysiology, and the absence of biologically grounded subtypes often results in a prolonged trial-and-error process when selecting effective treatments. This has motivated efforts to identify biomarkers that may predict individual treatment responses. Although mirtazapine is widely used and its efficacy is well established in clinical settings, neuroscientific studies on its treatment response remain limited relative to other antidepressants. To address this gap, this study examined pre-treatment pathophysiological neural features associated with subsequent response to mirtazapine. Sixty-seven individuals with MDD underwent functional magnetic resonance imaging during a conditioned reward task and then received monotherapy with mirtazapine or one of two comparator antidepressants (agomelatine or a selective serotonin reuptake inhibitor). Mirtazapine responders demonstrated increased pre-treatment activation in core components of the mesolimbic dopaminergic pathway, particularly the ventral tegmental area and ventral striatum, as well as in prefrontal and functionally connected regions implicated in reward evaluation, reward-related behavioral inhibition, and reward-based decision-making. Importantly, many of these response-related activations were specific to the mirtazapine group. These findings suggest that altered engagement of mesolimbic dopaminergic pathways and prefrontal regulatory networks during reward processing may characterize an MDD subtype responsive to mirtazapine, and that such patterns may serve as biomarkers for identifying patients likely to benefit from this treatment.
- 1 June 2026
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 27 (6) , 614-622
Investigation of the impact of rs3025343 near the dopamine ß-hydroxylase ( DBH ) gene on reward-related responses within the mesolimbic dopamine system
Norepinephrine plays a modulatory role in reward processing (Ferrucci et al. 2013; Fox and Lobo 2019). Alterations in the brain circuit that underlies reward processing are known to contribute to n...
- 1 June 2026
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 27 (6) , 614-622
Investigation of the impact of rs3025343 near the dopamine ß-hydroxylase ( DBH ) gene on reward-related responses within the mesolimbic dopamine system
Norepinephrine plays a modulatory role in reward processing (Ferrucci et al. 2013; Fox and Lobo 2019). Alterations in the brain circuit that underlies reward processing are known to contribute to n...
- Open Access
Exploratory Deep Phenotyping of Early Antidepressant Treatment Effects in a Longitudinal, Double-Blind, Randomized, Controlled, Parallel-Group Pre-Post Design – a Study Protocol from Research Consortium OptiMD
Background: A better understanding of neurobiological mechanisms behind clinical depression and optimization of pharmacological treatment options remain enormous challenges. Early subtyping of depression might be achieved by discovering reliable trait markers or by early detection of changes in potential state markers, for example during the first days of antidepressant treatment. Objective: The primary objective of this trial was to explore early neurobiological dynamics during the first week of antidepressant treatment within the same drug-naïve inpatients in a large deep-phenotyping exploration applying various measurement modalities as described below. Methods: A longitudinal deep-phenotyping experimental design involved holistic measurements of various markers with state-of-the art technology over five axes of investigation: MR neuroimaging, dexamethasone/CRH-testing, gut microbiome composition, inflammatory proteome and lipidomics. Therapy during these measurements was controlled and standardized by conducting a double-blind, randomized parallel group design with four balanced arms during the first seven days of medication that encompassed three common first-line, yet pharmacologically distinguishable, antidepressants (escitalopram, mirtazapine, agomelatine) or placebo. The complete trial period has been 60 days including a third major longitudinal point of investigation at the end of trial. An additional control cohort with matched healthy volunteers was participating in the same set of investigations as patients at baseline, except dexamethasone/CRH-testing. Trial status: This trial has extensively served two subprojects of the German National Research Consortium OptiMD. It has been registered at the European Clinical Trials Register with identifier 2013-003370-27 and was initiated in January 2016. Recruitment of 70 inpatients and 25 healthy participants has been completed in August 2021 without any known harms in regard to study participation. Collection of data is still ongoing and hence, databases are not yet closed. Analyses of first complete datasets have begun and we hope that our deep-phenotyping exploration might contribute to new perspectives on clinical depression and its treatment. Protocol outline:
Open AccessExploratory Deep Phenotyping of Early Antidepressant Treatment Effects in a Longitudinal, Double-Blind, Randomized, Controlled, Parallel-Group Pre-Post Design – a Study Protocol from Research Consortium OptiMD
Background: A better understanding of neurobiological mechanisms behind clinical depression and optimization of pharmacological treatment options remain enormous challenges. Early subtyping of depression might be achieved by discovering reliable trait markers or by early detection of changes in potential state markers, for example during the first days of antidepressant treatment. Objective: The primary objective of this trial was to explore early neurobiological dynamics during the first week of antidepressant treatment within the same drug-naïve inpatients in a large deep-phenotyping exploration applying various measurement modalities as described below. Methods: A longitudinal deep-phenotyping experimental design involved holistic measurements of various markers with state-of-the art technology over five axes of investigation: MR neuroimaging, dexamethasone/CRH-testing, gut microbiome composition, inflammatory proteome and lipidomics. Therapy during these measurements was controlled and standardized by conducting a double-blind, randomized parallel group design with four balanced arms during the first seven days of medication that encompassed three common first-line, yet pharmacologically distinguishable, antidepressants (escitalopram, mirtazapine, agomelatine) or placebo. The complete trial period has been 60 days including a third major longitudinal point of investigation at the end of trial. An additional control cohort with matched healthy volunteers was participating in the same set of investigations as patients at baseline, except dexamethasone/CRH-testing. Trial status: This trial has extensively served two subprojects of the German National Research Consortium OptiMD. It has been registered at the European Clinical Trials Register with identifier 2013-003370-27 and was initiated in January 2016. Recruitment of 70 inpatients and 25 healthy participants has been completed in August 2021 without any known harms in regard to study participation. Collection of data is still ongoing and hence, databases are not yet closed. Analyses of first complete datasets have begun and we hope that our deep-phenotyping exploration might contribute to new perspectives on clinical depression and its treatment. Protocol outline:
- Open Access
Neuropathophysiological changes associated with mirtazapine treatment response in major depressive disorder: insights into bottom-up dopaminergic pathways and prefrontal control networks
Due to the heterogeneity in symptoms and underlying biological mechanisms of major depressive disorder (MDD), as well as the lack of biologically validated approaches for subtyping, effective treatment often requires a prolonged trial-and-error process. This heterogeneity underscores the need for objective biomarkers that can predict individual treatment responses and guide antidepressant selection. Although mirtazapine is widely used and its efficacy is well established in clinical settings, neuroscientific studies on its treatment response remain limited relative to other antidepressants. To address this gap, the present study investigated pathophysiological changes in MDD patients that were associated with subsequent treatment response to mirtazapine, using functional magnetic resonance imaging with a conditioned reward task. Sixty-seven individuals diagnosed with MDD were enrolled and treated with either mirtazapine or one of two comparator antidepressants: agomelatine or a selective serotonin reuptake inhibitor. Participants were classified as responders or non-responders after six weeks of treatment. Mirtazapine responders demonstrated increased pre-treatment activation in core components of the mesolimbic dopaminergic pathway, particularly the ventral tegmental area and ventral striatum, as well as in prefrontal and functionally connected regions implicated in reward evaluation, reward-related behavioral inhibition, and reward-based decision-making. Importantly, many of these response-related activations were specific to the mirtazapine group. These findings suggest that the observed activation patterns may reflect alterations in the mesolimbic dopaminergic pathway and prefrontal regulatory networks during reward processing, which may characterize the pathophysiological brain features of MDD patients who respond to mirtazapine treatment. Moreover, these activation patterns may serve as promising biomarkers for identifying an MDD subtype more likely to benefit from mirtazapine.
Open AccessNeuropathophysiological changes associated with mirtazapine treatment response in major depressive disorder: insights into bottom-up dopaminergic pathways and prefrontal control networks
Due to the heterogeneity in symptoms and underlying biological mechanisms of major depressive disorder (MDD), as well as the lack of biologically validated approaches for subtyping, effective treatment often requires a prolonged trial-and-error process. This heterogeneity underscores the need for objective biomarkers that can predict individual treatment responses and guide antidepressant selection. Although mirtazapine is widely used and its efficacy is well established in clinical settings, neuroscientific studies on its treatment response remain limited relative to other antidepressants. To address this gap, the present study investigated pathophysiological changes in MDD patients that were associated with subsequent treatment response to mirtazapine, using functional magnetic resonance imaging with a conditioned reward task. Sixty-seven individuals diagnosed with MDD were enrolled and treated with either mirtazapine or one of two comparator antidepressants: agomelatine or a selective serotonin reuptake inhibitor. Participants were classified as responders or non-responders after six weeks of treatment. Mirtazapine responders demonstrated increased pre-treatment activation in core components of the mesolimbic dopaminergic pathway, particularly the ventral tegmental area and ventral striatum, as well as in prefrontal and functionally connected regions implicated in reward evaluation, reward-related behavioral inhibition, and reward-based decision-making. Importantly, many of these response-related activations were specific to the mirtazapine group. These findings suggest that the observed activation patterns may reflect alterations in the mesolimbic dopaminergic pathway and prefrontal regulatory networks during reward processing, which may characterize the pathophysiological brain features of MDD patients who respond to mirtazapine treatment. Moreover, these activation patterns may serve as promising biomarkers for identifying an MDD subtype more likely to benefit from mirtazapine.
- Open Access
- 4 August 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-17
Use of Artificial Intelligence in Psychiatric Research and Practice: A Qualitative Interview Study with Experts from Psychiatry, Computer Science and Philosophy in Germany
Background: The use of artificial intelligence (AI) in psychiatry holds promise for diagnosis, therapy, and the categorization of mental disorders. At the same time, it raises significant theoretical and ethical concerns. The debate appears polarized, with proponents and critics seemingly irreconcilably opposed. On the one hand, AI is heralded as a transformative force poised to revolutionize psychiatric research and practice. On the other hand, it is depicted as a harbinger of dehumanization. To better understand this dichotomy, it is essential to identify and critically examine the underlying arguments. To what extent does the use of AI challenge the theoretical assumptions of psychiatric diagnostics? What implications does it have for patient care, and how does it influence the professional self-concept of psychiatrists? Methods: To explore these questions, we conducted 15 semi-structured interviews with experts from psychiatry, computer science, and philosophy. The findings were analyzed using a structuring qualitative content analysis. Results: The analysis focuses on the significance of AI for psychiatric diagnosis and care, as well as on its implications for the identity of psychiatry. We identified different lines of argument suggesting that expert views on AI in psychiatry hinge on the types of data considered relevant and on whether core human capacities in diagnosis and treatment are viewed as replicable by AI. Conclusions: The results provide a mapping of diverse perspectives, offering a basis for more detailed analysis of theoretical and ethical issues of AI in psychiatry, as well as for the adaptation of psychiatric education.
- 4 August 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-17
Open AccessUse of Artificial Intelligence in Psychiatric Research and Practice: A Qualitative Interview Study with Experts from Psychiatry, Computer Science and Philosophy in Germany
Background: The use of artificial intelligence (AI) in psychiatry holds promise for diagnosis, therapy, and the categorization of mental disorders. At the same time, it raises significant theoretical and ethical concerns. The debate appears polarized, with proponents and critics seemingly irreconcilably opposed. On the one hand, AI is heralded as a transformative force poised to revolutionize psychiatric research and practice. On the other hand, it is depicted as a harbinger of dehumanization. To better understand this dichotomy, it is essential to identify and critically examine the underlying arguments. To what extent does the use of AI challenge the theoretical assumptions of psychiatric diagnostics? What implications does it have for patient care, and how does it influence the professional self-concept of psychiatrists? Methods: To explore these questions, we conducted 15 semi-structured interviews with experts from psychiatry, computer science, and philosophy. The findings were analyzed using a structuring qualitative content analysis. Results: The analysis focuses on the significance of AI for psychiatric diagnosis and care, as well as on its implications for the identity of psychiatry. We identified different lines of argument suggesting that expert views on AI in psychiatry hinge on the types of data considered relevant and on whether core human capacities in diagnosis and treatment are viewed as replicable by AI. Conclusions: The results provide a mapping of diverse perspectives, offering a basis for more detailed analysis of theoretical and ethical issues of AI in psychiatry, as well as for the adaptation of psychiatric education.
- 17 October 2024
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 275 (2) , 499-510
DNAJC13 influences responses of the extended reward system to conditioned stimuli: a genome-wide association study
Reward system dysfunction is implicated in the pathogenesis of major psychiatric disorders. We conducted a genome-wide association study (GWAS) to identify genes that influence activation strength of brain regions within the extended reward system in humans. A homogeneous sample of 214 participants was genotyped and underwent functional magnetic resonance imaging (fMRI). All subjects performed the ‘desire-reason dilemma’ (DRD) paradigm allowing systematic investigation of systems-level mechanisms of reward processing in humans. As a main finding, we identified the single nucleotide variant rs113408797 in the DnaJ Heat Shock Protein Family Member C13 gene [DNAJC13], alias Receptor-Mediated Endocytosis 8 [RME-8], that was associated with the activation strength of the ventral tegmental area (VTA; p = 2.50E-07) and the nucleus accumbens (NAcc; p = 5.31E-05) in response to conditioned reward stimuli. Moreover, haplotype analysis assessing the information across the entire DNAJC13 locus demonstrated an impact of a five-marker haplotype on VTA activation (p = 3.21E-07), which further corroborates a link between this gene and reward processing. The present findings provide first direct empirical evidence that genetic variation of DNAJC13 influences neural responses within the extended reward system to conditioned stimuli. Further studies are required to investigate the role of this gene in the pathogenesis and pathophysiology of neuropsychiatric disorders.
- 17 October 2024
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 275 (2) , 499-510
DNAJC13 influences responses of the extended reward system to conditioned stimuli: a genome-wide association study
Reward system dysfunction is implicated in the pathogenesis of major psychiatric disorders. We conducted a genome-wide association study (GWAS) to identify genes that influence activation strength of brain regions within the extended reward system in humans. A homogeneous sample of 214 participants was genotyped and underwent functional magnetic resonance imaging (fMRI). All subjects performed the ‘desire-reason dilemma’ (DRD) paradigm allowing systematic investigation of systems-level mechanisms of reward processing in humans. As a main finding, we identified the single nucleotide variant rs113408797 in the DnaJ Heat Shock Protein Family Member C13 gene [DNAJC13], alias Receptor-Mediated Endocytosis 8 [RME-8], that was associated with the activation strength of the ventral tegmental area (VTA; p = 2.50E-07) and the nucleus accumbens (NAcc; p = 5.31E-05) in response to conditioned reward stimuli. Moreover, haplotype analysis assessing the information across the entire DNAJC13 locus demonstrated an impact of a five-marker haplotype on VTA activation (p = 3.21E-07), which further corroborates a link between this gene and reward processing. The present findings provide first direct empirical evidence that genetic variation of DNAJC13 influences neural responses within the extended reward system to conditioned stimuli. Further studies are required to investigate the role of this gene in the pathogenesis and pathophysiology of neuropsychiatric disorders.
- Open Access
- 14 June 2024
- Published by Wiley in Brain and Behavior
- Vol. 14 (6) , e3545
Task‐induced deactivation dysfunction during reward processing is associated with low self‐esteem in a possible subtype of major depression
Introduction: Low self‐esteem is a frequent symptom in major depressive disorder (MDD). This functional magnetic resonance imaging study investigated whether MDD patients with low self‐esteem show a distinct neural pathophysiology. Previous studies linked low self‐esteem to reduced task‐induced deactivation of the pregenual anterior cingulate cortex (pgACC) as a part of the default mode network, and to reduced connectivity between pgACC and reward system. Goya‐Maldonado et al. identified an MDD subtype with pgACC and ventral striatal overactivations during reward processing. We hypothesized that this subtype might be characterized by low self‐esteem.Methods: Eighty‐three MDD patients performed the desire–reason dilemma task and completed the Rosenberg Self‐Esteem Scale (RSES). Brain activity during bottom‐up reward processing was regressed upon the RSES scores, controlling for depression severity measured by the Montgomery–Åsberg Depression Rating Scale. To corroborate the findings, we compared self‐esteem scores between patient subgroups with impaired task‐induced deactivation (n = 31) and with preserved task‐induced deactivation (n = 31) of the pgACC.Results: Consistent with our a priori hypothesis, activity in a bilateral fronto‐striatal network including pgACC and ventral striatum correlated negatively with RSES scores, also when controlling for depression severity. In the additional analysis, patients with impaired task‐induced pgACC deactivation showed lower self‐esteem (t (52.82) = −2.27; p = .027, d = 0.58) compared to those with preserved task‐induced pgACC deactivation.Conclusions: We conclude that low self‐esteem in MDD patients is linked to a task‐induced deactivation dysfunction of the pgACC. Our findings suggest that a previously described possible subtype of MDD with pgACC and ventral striatal overactivations during reward processing is clinically characterized by low self‐esteem.
- 14 June 2024
- Published by Wiley in Brain and Behavior
- Vol. 14 (6) , e3545
Open AccessTask‐induced deactivation dysfunction during reward processing is associated with low self‐esteem in a possible subtype of major depression
Introduction: Low self‐esteem is a frequent symptom in major depressive disorder (MDD). This functional magnetic resonance imaging study investigated whether MDD patients with low self‐esteem show a distinct neural pathophysiology. Previous studies linked low self‐esteem to reduced task‐induced deactivation of the pregenual anterior cingulate cortex (pgACC) as a part of the default mode network, and to reduced connectivity between pgACC and reward system. Goya‐Maldonado et al. identified an MDD subtype with pgACC and ventral striatal overactivations during reward processing. We hypothesized that this subtype might be characterized by low self‐esteem.Methods: Eighty‐three MDD patients performed the desire–reason dilemma task and completed the Rosenberg Self‐Esteem Scale (RSES). Brain activity during bottom‐up reward processing was regressed upon the RSES scores, controlling for depression severity measured by the Montgomery–Åsberg Depression Rating Scale. To corroborate the findings, we compared self‐esteem scores between patient subgroups with impaired task‐induced deactivation (n = 31) and with preserved task‐induced deactivation (n = 31) of the pgACC.Results: Consistent with our a priori hypothesis, activity in a bilateral fronto‐striatal network including pgACC and ventral striatum correlated negatively with RSES scores, also when controlling for depression severity. In the additional analysis, patients with impaired task‐induced pgACC deactivation showed lower self‐esteem (t (52.82) = −2.27; p = .027, d = 0.58) compared to those with preserved task‐induced pgACC deactivation.Conclusions: We conclude that low self‐esteem in MDD patients is linked to a task‐induced deactivation dysfunction of the pgACC. Our findings suggest that a previously described possible subtype of MDD with pgACC and ventral striatal overactivations during reward processing is clinically characterized by low self‐esteem.
- Open Access
- 2 March 2024
- Published by Elsevier in Schizophrenia Research
- Vol. 266, 237-248
A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort
- 2 March 2024
- Published by Elsevier in Schizophrenia Research
- Vol. 266, 237-248
Open AccessA naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort
- 29 January 2024
- Published by Springer Nature in Nature Mental Health
- Vol. 2 (3) , 310-319
Asymmetry, cytoarchitectonic morphology and genetics associated with Broca’s area in schizophrenia
- 29 January 2024
- Published by Springer Nature in Nature Mental Health
- Vol. 2 (3) , 310-319
Asymmetry, cytoarchitectonic morphology and genetics associated with Broca’s area in schizophrenia